arXiv preprint ·

OpenMTB-Audit: Exposing Over-Refusal and Clinical Expert Perspectives in LLM-Based Molecular Tumor Board Safety Evaluation

Negin Ashrafi, Jia Luo, Stacey M. Frumm and Roxana Daneshjou

Published
Source
arXiv preprint, posted before peer review
Original
Read it at arXiv
Topics
Artificial IntelligenceMachine Learning

Abstract

Molecular tumor boards integrate genomic findings, clinical context, and therapeutic evidence to support precision oncology. As AI enters this workflow, a key safety challenge is distinguishing truly unsupported recommendations from evidence-supported options that still require oncologist review because of incomplete information, poor ECOG performance status, or other clinical caveats. We introduce OpenMTB-Audit, an open-source benchmark of 500 synthetic non-small cell lung cancer cases spanning five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. Across eight large language model configurations, we identify pervasive over-refusal: all LLM configurations failed to retain the Partially Supported label in 83.3-100% of true Partially Supported cases, achieving high aggregate safety scores through label collapse rather than clinically calibrated reasoning. To address this limitation, we developed MTB-AuditAgent, a deterministic seven-module framework separating evidence verification, missing-information detection, safety classification, and abstention. It reduces over-refusal to 6.7% and achieves 91.2% accuracy (95% CI: 88.6-93.6%). A two-oncologist annotation study found disagreement concentrated at the boundary between information sufficiency and treatment optimization, underscoring the need to preserve clinically meaningful distinctions.

The authors’ abstract, as arXiv lists it. arXiv’s listings, abstracts included, are free for anyone to reuse.

Read it on ReadSearch

Each opens after you create an account, and brings you back to this paper.

Already a reader? Sign in

All new papers in Artificial Intelligence

Get the few papers worth your time in Artificial Intelligence every morning.

ReadSearch reads the new papers in your field each day and brings you the few worth reading, each with its key finding in a sentence.

Papers belong to their authors and publishers; every page here links to the original. All research topics